WILMINGTON, N.C., March 27 /PRNewswire-FirstCall/ --
aaiPharma Inc. (Nasdaq: AAII) announced today the launch of the 75 mg and
100 mg Azasan(TM) (azathioprine tablets) products into the marketplace. These
proprietary new dosage forms are now commercially available, and promotion is
underway.
In addition, the Company reported that IMS prescription data for the 50 mg
dosage form of Azasan(TM) is trending very positively. Since the July 2002
launch of aaiPharma's 50 mg product, aaiPharma's share of total azathioprine
prescriptions has increased from 2% in August 2002, the month after the
Company launched the product, to 31.5% as of March 14, 2003.
"Our market share for the Azasan(TM) 50 mg product is trending nicely,"
according to Mr. David Hurley, President of the Pharmaceuticals Division of
aaiPharma. "This trend, coupled with the launch of our proprietary Azasan(TM)
dosage strengths, demonstrates our ability to innovate established products
through science, and execute on our sales and marketing strategy."
The Company indicated that its field organization, which now numbers more
than 80 representatives, was trained last month at the Company's National
Sales Meeting, and began detailing the new Azasan(TM) products this week.
Previously unavailable, these new 75 mg and 100 mg Azasan(TM) tablet
strengths will provide physicians with more flexible dosage options and
contribute to enhanced patient compliance. With this launch and the Company's
currently marketed 50 mg dosage form, aaiPharma now offers the most
comprehensive line of azathioprine dosage forms on the market today.
About aaiPharma
aaiPharma Inc. is a leading, science-based specialty pharmaceutical
company with corporate headquarters in Wilmington, North Carolina. With more
than 23 years of drug development expertise and a proven sales and marketing
track record, the Company is focused on acquiring, improving and marketing
well-known, branded medicines in pain management, gastroenterology and
critical care. In addition to its branded product portfolio and robust
pipeline, aaiPharma continues to offer comprehensive drug development services
to the pharmaceutical, biotechnology, generic and device industries through
its services division, AAI International. For more information, please visit
aaiPharma's website at http://www.aaipharma.com.
Forward Looking Statements
Information in this press release contains certain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities and Exchange Act of 1934, including the
statements pertaining to Azasan(TM) product and product line sales growth
trends, the future commercial and medical attractiveness and usefulness of the
new dosage forms for patients and patient compliance, and future development,
commercialization and growth of the products in the Company's pipeline and
portfolio. The "forward-looking statements" herein involve risks and
uncertainties that could cause actual results to differ materially, including,
without limitation, risks and uncertainties pertaining to actual future market
growth for these azathioprine products, actual commercial and medical
attractiveness of the new dosage forms, and aaiPharma's ability to
successfully find, acquire, finance, develop, improve, enhance, obtain timely
regulatory approval for, maximize the value of, extend product life cycles of,
conduct successful research on, renew marketing of, and sell, on a
commercially profitable basis, pharmaceutical products without adversely
affecting its client relationships or business opportunities; to obtain, use,
enforce, defend and license valid and commercially valuable patents; to obtain
and enforce existing and future contracts with major pharmaceutical companies
for significant royalties and other consideration; and on the commercial
success of the contemplated products. Additional factors that may cause the
actual results to differ materially are discussed in aaiPharma's recent
filings with the Securities and Exchange Commission, including, but not
limited to, its Annual Report on Form 10-K filed on March 11, 2002, including
its exhibits; its Form 10-Q filed on August 14, 2002, including Exhibit 99.1
thereto; its Form 10-Q filed on November 14, 2002; its Form 8-Ks; and its
other periodic filings.
Azasan(TM) is a trademark of aaiPharma.
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
media, Andrea L. Johnston, Vice President,
Corporate Communications, +1-910-254-7340, or investors, James B.
Sloan, Jr., Senior Vice President, Corporate Finance,
+1-910-254-7690, both of aaiPharma Inc.
EDITOR'S ADVISORY: Photo of Azasan(TM) tablets available
electronically from the Corporate Communications office of
aaiPharma.
|
